Polypodium leucotomos Extract use to prevent and reduce the risk of infectious diseases in high performance athletes

Clicks: 348
ID: 6431
2012
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #176 of 1,693 articles by views in Infection and drug resistance

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 1,693 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Polypodium leucotomos Extract use to prevent and reduce the risk of infectious diseases in high performance athletes Bartolomé Marí Solivellas, Teo Cabanes MartínSports Medicine Service, Mallorca Regional Government, Mallorca, SpainObjective: Many components of the immune system undergo adverse changes during intense physical activity in athletes, leading to a heightened risk of respiratory tract infections. This study evaluated the reduction in infectious processes in athletes due to intensive training with anapsos.Methods: The study compared athletes who took 480 mg Polypodium leucotomos Extract (Armaya fuerte; Centrum laboratories, Alicante, Spain) twice daily for 3 months (n
Reference Key
bartolom2012polypodiuminfection Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Bartolomé Marí Solivellas;Teo Cabanes Martín and
Journal Infection and drug resistance
Year 2012
DOI
10.2147/IDR.S29113
URL
Keywords
Infectious and parasitic diseases

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.